Anxiety DisordersTRAbeeNCT05016843
The Study of Internet-delivered, Transdiagnostic Treatments for Anxiety and Depression
A study testing Treatment condition: Internet-administered Unified protocol, Treatment condition: Internet-administered Affect phobia treatment and Treatment length: 8 weeks in people with Anxiety Disorders and Depression, run by Stockholm University at 1 site in Sweden.
Trial summary
Anxiety and depression are common psychiatric disorders, resulting in suffering and impaired functioning for the individual. Today, most psychological treatments are disorder specific, even tough comorbidity between depression and anxiety and different anxiety disorders is rule rather than exception. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Anxiety Disorders, Depression
- What is being tested?
- Treatment condition: Internet-administered Unified protocol, Treatment condition: Internet-administered Affect phobia treatment and Treatment length: 8 weeks
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,477 participants
- Where
- 1 siteSweden
- Study dates
- 25 Aug 2021to 22 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Be able to read and write Swedish,
- access to a mobile phone/computer,
- 18 years or older,
- GAD-7 ≥ 5 and/or
- PHQ-9 ≥ 10.
Who cannot join
- Partaking in other psychological treatment,
- has started or adjusted treatment with psychopharmacological drugs for anxiety, worry or depression within the nearest month,
- severe depression (PHQ-9 ≥ 20) or suicidal (PHQ-9, item 9>2).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Study of Internet-delivered, Transdiagnostic Treatments for Anxiety and Depression ("TRAnsdiagnostisk BEhandling (Elektronisk)")
Anxiety and depression are common psychiatric disorders, resulting in suffering and impaired functioning for the individual. Today, most psychological treatments are disorder specific, even tough comorbidity between depression and anxiety and different anxiety disorders is rule rather than exception. Transdiagnostic treatments target the common features between depression and anxiety disorders and has shown to be as effective as disorder specific treatments in reducing symptoms of the disorders. Unified protocol and Affect phobia treatment are two types of transdiagnostic treatments that, to our knowledge, never been compared in research before. Internet-administered treatment presents a promising way to increase availability of psychotherapeutic interventions such as transdiagnostic treatments. However, questions regarding the optimal treatment length and level of support remain unanswered. The aim of this study is to examine two internet-administered transdiagnostic treatments and their effect on anxiety and depression, and to investigate the impact of treatment length and access to a moderated forum.
The study will investigate three factors: type of transdiagnostic treatment, length of treatment and whether patients have access to a moderated forum or not. 2400 participants with anxiety and/or depression will be randomly assigned to one of 12 subgroups and subsequently offered treatment based on differing combinations of the previously mentioned factors (200 participants/arm). The treatment conditions are internet-administered cognitive, behavioral treatment (CBT) Unified protocol and the psychodynamic Affect phobia treatment as well as a waitlist control group. Participants will also be randomized to either 8 or 16 weeks of treatment and access to a moderated forum or not.
Primary outcome measures will be the Patient Health Questionnaire, the Generalized Anxiety Disorder 7-item scale and the Brief Quality of Life scale. Negative effects of treatment will also be assessed. In addition to pre- and post-treatment measurements, the study includes one mid-treatment and three follow-up assessments (6, 12 and 24 months).
- Conditions
- Anxiety Disorders, Depression
- Being tested
- Treatment condition: Internet-administered Unified protocol, Treatment condition: Internet-administered Affect phobia treatment, Treatment condition: Waitlist control, Treatment length: 8 weeks, Treatment length: 16 weeks
- Medical subject headings
- Anxiety Disorders, Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Treatment condition: Internet-administered Unified protocolBehavioural
Treatment condition:
The cognitive, behavioral treatment Unified protocol is a transdiagnostic treatment for anxiety and depression. Participants are taught five techniques in order to find new and more helpful ways to react to hindering thoughts and feelings: mindfulness, cognitive flexibility, identify and reduce behavioral avoidance, increase willingness to experience physiological sensations and exposure. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week.
Treatment condition: Internet-administered Affect phobia treatmentBehavioural
The aim of psychodynamic Affect phobia treatment is for the patient to reach an intellectual and emotional understanding of his/hers problems. The goal of the treatment is for participants to decrease emotional avoidance and start to approach emotions and increase emotional awareness. Participants are taught this through linking their symptoms to their emotional avoidance, observe frequent and maladaptive patterns in relationships and see how these are linked to emotional avoidance. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week.
Treatment condition: Waitlist controlOther
The waitlist condition is a control condition without any intervention.
Treatment length: 8 weeksOther
Participants will partake in their treatment condition for 8 weeks.
Treatment length: 16 weeksOther
Participants will partake in their treatment condition for 16 weeks.
Access to a moderated forumOther
During their treatment, participants will have access to a discussion forum moderated by a clinician. Participants are encouraged to discuss questions and experiences related to their treatment condition.
No access to a moderated forumOther
Participants will not have access to a moderated forum, hence their treatment is self-guided.
| Study group | Role | What they receive |
|---|---|---|
| CBT, 8 weeks and access to forum. | Experimental | Not described Receives: Behavioral: Treatment condition: Internet-administered Unified protocol; Other: Treatment length: 8 weeks; Other: Access to a moderated forum |
| CBT, 16 weeks and access to forum. | Experimental | Not described Receives: Behavioral: Treatment condition: Internet-administered Unified protocol; Other: Treatment length: 16 weeks; Other: No access to a moderated forum |
| CBT, 8 weeks and no access to forum. | Experimental | Not described Receives: Behavioral: Treatment condition: Internet-administered Unified protocol; Other: Treatment length: 8 weeks; Other: No access to a moderated forum |
| CBT, 16 weeks and no access to forum. | Experimental | Not described Receives: Behavioral: Treatment condition: Internet-administered Unified protocol; Other: Treatment length: 16 weeks; Other: Access to a moderated forum |
| Psychodynamic therapy, 8 weeks and access to forum. | Experimental | Not described Receives: Behavioral: Treatment condition: Internet-administered Affect phobia treatment; Other: Treatment length: 8 weeks; Other: Access to a moderated forum |
| Psychodynamic therapy, 16 weeks and access to forum. | Experimental | Not described Receives: Behavioral: Treatment condition: Internet-administered Affect phobia treatment; Other: Treatment length: 16 weeks; Other: Access to a moderated forum |
| Psychodynamic therapy, 8 weeks and no access to forum. | Experimental | Not described Receives: Behavioral: Treatment condition: Internet-administered Affect phobia treatment; Other: Treatment length: 8 weeks; Other: No access to a moderated forum |
| Psychodynamic therapy, 16 weeks and no access to forum. | Experimental | Not described Receives: Behavioral: Treatment condition: Internet-administered Affect phobia treatment; Other: Treatment length: 16 weeks; Other: No access to a moderated forum |
| Waitlist, 8 weeks and access to forum. | Experimental | Not described Receives: Other: Treatment condition: Waitlist control; Other: Treatment length: 8 weeks; Other: Access to a moderated forum |
| Waitlist, 16 weeks and access to forum. | Experimental | Not described Receives: Other: Treatment condition: Waitlist control; Other: Treatment length: 16 weeks; Other: Access to a moderated forum |
| Waitlist, 8 weeks and no access to forum. | Experimental | Not described Receives: Other: Treatment condition: Waitlist control; Other: Treatment length: 8 weeks; Other: No access to a moderated forum |
| Waitlist, 16 weeks and no access to forum. | Experimental | Not described Receives: Other: Treatment condition: Waitlist control; Other: Treatment length: 16 weeks; Other: No access to a moderated forum |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient Health Questionnaire 9-item scale (PHQ-9)
The PHQ-9 features nine items for assessing depression in a clinical context and screening of depression in the general population.
Measured: Through study completion, an average of 2 years.
Generalised Anxiety Disorder 7- item scale (GAD-7)
The GAD-7 features seven items for assessing anxiety and screening for generalized anxiety disorder.
Measured: Through study completion, an average of 2 years.
Brunnsviken Brief Quality of Life Scale (BBQ)
The BBQ features 12 items concerning 6 areas of life rated on importance and satisfaction.
Measured: Through study completion, an average of 2 years.
Secondary outcomes (3)
The Personality Inventory for DSM Short Form (PID-5)
The PID-5 is a self-rated measure of personality-related problems featuring 25 items.
Measured: Baseline only.
Negative Effects Questionnaire (NEQ)
The NEQ measures unwanted effects of treatments.
Measured: At post-treatment only (which is week 8 or 16 depending on treatment allocation).
Reflective Functioning Questionnaire 8 (RFQ-8)
RFQ features 8 items assessing the ability to understand mental states of the self and others.
Measured: Through study completion, an average of 2 years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Aug 2021
- Study start25 Aug 2021
- Primary completion22 Jan 2026
- Study completion22 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Anxiety DisordersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Enrolment
- 2,477 participants (actual)
Sponsor and investigators
- Lead sponsor
- Stockholm University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Per Carlbring, Stockholm University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05016843
- Sponsor's protocol ID
- TRAbee
- Acronym
- TRAbee
- Status last verified
- Jan 2026
- First submitted
- 8 Aug 2021
- Last updated
- 26 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Lindqvist K, Mechler J, Hlynsson JI, Andersson G, Carlbring P. Internet-delivered unguided psychodynamic vs. cognitive behavior therapy for anxiety and depression symptoms: A large, full factorial randomized controlled trial on treatment length and peer support. Internet Interv. 2026 Jul 16;45:100980. doi: 10.1016/j.invent.2026.100980. eCollection 2026 Sep.
PubMed 42633284Hlynsson JI, Carlbring P. Diagnostic accuracy and clinical utility of the PHQ-2 and GAD-2: a comparison with long-format measures for depression and anxiety. Front Psychol. 2024 May 10;15:1259997. doi: 10.3389/fpsyg.2024.1259997. eCollection 2024.
PubMed 38800678Hlynsson JI, Lindner P, Barri B, Carlbring P. Exploring cutoff points and measurement invariance of the Brunnsviken brief quality of life inventory. Front Psychol. 2024 Jan 8;14:1305682. doi: 10.3389/fpsyg.2023.1305682. eCollection 2023.
PubMed 38259555
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Study of Internet-delivered, Transdiagnostic Treatments for Anxiety and Depression ("TRAnsdiagnostisk BEhandling (Elektronisk)")
- ClinicalTrials.gov ID
- NCT05016843
- Acronym / sponsor ID
- TRAbee / TRAbee
- Conditions
- Anxiety Disorders, Depression
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 2,477 participants (actual)
- Lead sponsor
- Stockholm UniversityUniversity, hospital or other
- Study start
- 25 Aug 2021 (actual)
- Primary completion
- 22 Jan 2026 (actual)
- Study completion
- 22 Jan 2026 (actual)
- First posted
- 23 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Anxiety and depression are common psychiatric disorders, resulting in suffering and impaired functioning for the individual. Today, most psychological treatments are disorder specific, even tough comorbidity between depression and anxiety and different anxiety disorders is rule rather than exception. Transdiagnostic treatments target the common features between depression and anxiety disorders and has shown to be as effective as disorder specific treatments in reducing symptoms of the disorders. Unified protocol and Affect phobia treatment are two types of transdiagnostic treatments that, to our knowledge, never been compared in research before. Internet-administered treatment presents a promising way to increase availability of psychotherapeutic interventions such as transdiagnostic treatments. However, questions regarding the optimal treatment length and level of support remain unanswered. The aim of this study is to examine two internet-administered transdiagnostic treatments and their effect on anxiety and depression, and to investigate the impact of treatment length and access to a moderated forum.
The study will investigate three factors: type of transdiagnostic treatment, length of treatment and whether patients have access to a moderated forum or not. 2400 participants with anxiety and/or depression will be randomly assigned to one of 12 subgroups and subsequently offered treatment based on differing combinations of the previously mentioned factors (200 participants/arm). The treatment conditions are internet-administered cognitive, behavioral treatment (CBT) Unified protocol and the psychodynamic Affect phobia treatment as well as a waitlist control group. Participants will also be randomized to either 8 or 16 weeks of treatment and access to a moderated forum or not.
Primary outcome measures will be the Patient Health Questionnaire, the Generalized Anxiety Disorder 7-item scale and the Brief Quality of Life scale. Negative effects of treatment will also be assessed. In addition to pre- and post-treatment measurements, the study includes one mid-treatment and three follow-up assessments (6, 12 and 24 months).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Number of arms
- 12
| Arm | Type | Receives |
|---|---|---|
| CBT, 8 weeks and access to forum. | Experimental | Behavioral: Treatment condition: Internet-administered Unified protocol, Other: Treatment length: 8 weeks, Other: Access to a moderated forum |
| CBT, 16 weeks and access to forum. | Experimental | Behavioral: Treatment condition: Internet-administered Unified protocol, Other: Treatment length: 16 weeks, Other: No access to a moderated forum |
| CBT, 8 weeks and no access to forum. | Experimental | Behavioral: Treatment condition: Internet-administered Unified protocol, Other: Treatment length: 8 weeks, Other: No access to a moderated forum |
| CBT, 16 weeks and no access to forum. | Experimental | Behavioral: Treatment condition: Internet-administered Unified protocol, Other: Treatment length: 16 weeks, Other: Access to a moderated forum |
| Psychodynamic therapy, 8 weeks and access to forum. | Experimental | Behavioral: Treatment condition: Internet-administered Affect phobia treatment, Other: Treatment length: 8 weeks, Other: Access to a moderated forum |
| Psychodynamic therapy, 16 weeks and access to forum. | Experimental | Behavioral: Treatment condition: Internet-administered Affect phobia treatment, Other: Treatment length: 16 weeks, Other: Access to a moderated forum |
| Psychodynamic therapy, 8 weeks and no access to forum. | Experimental | Behavioral: Treatment condition: Internet-administered Affect phobia treatment, Other: Treatment length: 8 weeks, Other: No access to a moderated forum |
| Psychodynamic therapy, 16 weeks and no access to forum. | Experimental | Behavioral: Treatment condition: Internet-administered Affect phobia treatment, Other: Treatment length: 16 weeks, Other: No access to a moderated forum |
| Waitlist, 8 weeks and access to forum. | Experimental | Other: Treatment condition: Waitlist control, Other: Treatment length: 8 weeks, Other: Access to a moderated forum |
| Waitlist, 16 weeks and access to forum. | Experimental | Other: Treatment condition: Waitlist control, Other: Treatment length: 16 weeks, Other: Access to a moderated forum |
| Waitlist, 8 weeks and no access to forum. | Experimental | Other: Treatment condition: Waitlist control, Other: Treatment length: 8 weeks, Other: No access to a moderated forum |
| Waitlist, 16 weeks and no access to forum. | Experimental | Other: Treatment condition: Waitlist control, Other: Treatment length: 16 weeks, Other: No access to a moderated forum |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Be able to read and write Swedish,
- access to a mobile phone/computer,
- 18 years or older,
- GAD-7 ≥ 5 and/or
- PHQ-9 ≥ 10.
Key exclusion criteria (3 listed)
- Partaking in other psychological treatment,
- has started or adjusted treatment with psychopharmacological drugs for anxiety, worry or depression within the nearest month,
- severe depression (PHQ-9 ≥ 20) or suicidal (PHQ-9, item 9>2).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Treatment condition: Internet-administered Unified protocolTreatment condition: The cognitive, behavioral treatment Unified protocol is a transdiagnostic treatment for anxiety and depression. Participants are taught five techniques in order to find new and more helpful ways to react to hindering thoughts and feelings: mindfulness, cognitive flexibility, identify and reduce behavioral avoidance, increase willingness to experience physiological sensations and exposure. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week. | Behavioural | CBT, 16 weeks and access to forum., CBT, 16 weeks and no access to forum., CBT, 8 weeks and access to forum., CBT, 8 weeks and no access to forum. |
| Treatment condition: Internet-administered Affect phobia treatmentThe aim of psychodynamic Affect phobia treatment is for the patient to reach an intellectual and emotional understanding of his/hers problems. The goal of the treatment is for participants to decrease emotional avoidance and start to approach emotions and increase emotional awareness. Participants are taught this through linking their symptoms to their emotional avoidance, observe frequent and maladaptive patterns in relationships and see how these are linked to emotional avoidance. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week. | Behavioural | Psychodynamic therapy, 16 weeks and access to forum., Psychodynamic therapy, 16 weeks and no access to forum., Psychodynamic therapy, 8 weeks and access to forum., Psychodynamic therapy, 8 weeks and no access to forum. |
| Treatment condition: Waitlist controlThe waitlist condition is a control condition without any intervention. | Other | Waitlist, 16 weeks and access to forum., Waitlist, 16 weeks and no access to forum., Waitlist, 8 weeks and access to forum., Waitlist, 8 weeks and no access to forum. |
| Treatment length: 8 weeksParticipants will partake in their treatment condition for 8 weeks. | Other | CBT, 8 weeks and access to forum., CBT, 8 weeks and no access to forum., Psychodynamic therapy, 8 weeks and access to forum., Psychodynamic therapy, 8 weeks and no access to forum., Waitlist, 8 weeks and access to forum., Waitlist, 8 weeks and no access to forum. |
| Treatment length: 16 weeksParticipants will partake in their treatment condition for 16 weeks. | Other | CBT, 16 weeks and access to forum., CBT, 16 weeks and no access to forum., Psychodynamic therapy, 16 weeks and access to forum., Psychodynamic therapy, 16 weeks and no access to forum., Waitlist, 16 weeks and access to forum., Waitlist, 16 weeks and no access to forum. |
| Access to a moderated forumDuring their treatment, participants will have access to a discussion forum moderated by a clinician. Participants are encouraged to discuss questions and experiences related to their treatment condition. | Other | CBT, 16 weeks and no access to forum., CBT, 8 weeks and access to forum., Psychodynamic therapy, 16 weeks and access to forum., Psychodynamic therapy, 8 weeks and access to forum., Waitlist, 16 weeks and access to forum., Waitlist, 8 weeks and access to forum. |
| No access to a moderated forumParticipants will not have access to a moderated forum, hence their treatment is self-guided. | Other | CBT, 16 weeks and access to forum., CBT, 8 weeks and no access to forum., Psychodynamic therapy, 16 weeks and no access to forum., Psychodynamic therapy, 8 weeks and no access to forum., Waitlist, 16 weeks and no access to forum., Waitlist, 8 weeks and no access to forum. |
Primary outcome
Patient Health Questionnaire 9-item scale (PHQ-9)
Time frame: Through study completion, an average of 2 years.
The PHQ-9 features nine items for assessing depression in a clinical context and screening of depression in the general population.
Generalised Anxiety Disorder 7- item scale (GAD-7)
Time frame: Through study completion, an average of 2 years.
The GAD-7 features seven items for assessing anxiety and screening for generalized anxiety disorder.
Brunnsviken Brief Quality of Life Scale (BBQ)
Time frame: Through study completion, an average of 2 years.
The BBQ features 12 items concerning 6 areas of life rated on importance and satisfaction.
3 secondary outcomes
The Personality Inventory for DSM Short Form (PID-5)
Time frame: Baseline only.
Negative Effects Questionnaire (NEQ)
Time frame: At post-treatment only (which is week 8 or 16 depending on treatment allocation).
Reflective Functioning Questionnaire 8 (RFQ-8)
Time frame: Through study completion, an average of 2 years.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2026.
- Derived from this study: PubMed 42633284Lindqvist K, Mechler J, Hlynsson JI, Andersson G, Carlbring P. Internet-delivered unguided psychodynamic vs. cognitive behavior therapy for anxiety and depression symptoms: A large, full factorial randomized controlled trial on treatment length and peer support. Internet Interv. 2026 Jul 16;45:100980. doi: 10.1016/j.invent.2026.100980. eCollection 2026 Sep.
- Derived from this study: PubMed 38800678Hlynsson JI, Carlbring P. Diagnostic accuracy and clinical utility of the PHQ-2 and GAD-2: a comparison with long-format measures for depression and anxiety. Front Psychol. 2024 May 10;15:1259997. doi: 10.3389/fpsyg.2024.1259997. eCollection 2024.
- Derived from this study: PubMed 38259555Hlynsson JI, Lindner P, Barri B, Carlbring P. Exploring cutoff points and measurement invariance of the Brunnsviken brief quality of life inventory. Front Psychol. 2024 Jan 8;14:1305682. doi: 10.3389/fpsyg.2023.1305682. eCollection 2023.
Related trials for Anxiety Disorders
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Recruiting
Effect of a Brief Daily Digital Meditation on Well-Being in US Young Adults (BEGIN II)
Mental Health and General Well-being
Not yet recruitingObservational study
Functional Impact of Psychological Symptoms in Patients With Superior Semicircular Canal Dehiscence Syndrome (SSCD): a National Cross-sectional Study
Superior Semicircular Canal Dehiscence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Treatment condition: Internet-administered Unified protocol, Treatment condition: Internet-administered Affect phobia treatment and Treatment length: 8 weeks in people with Anxiety Disorders and Depression, run by Stockholm University at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient Health Questionnaire 9-item scale (PHQ-9) (time frame: Through study completion, an average of 2 years.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05016843, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2026.